Kling Biotherapeutics Email Format

Biotechnology ResearchNorth Holland, Netherlands11-50 Employees

Kling Biotherapeutics is a clinical-stage biotechnology company based in Amsterdam, North Holland, focused on the discovery and development of antibody-based therapeutics. It maintains an owned portfolio of intellectual property around two approaches that enable simultaneous discovery of novel targets and isolation of fully human antibodies from patient-derived B cells. The discovery approach has yielded neutralizing antibodies for infectious diseases, and the platform is increasingly applied to B cells from cancer patients to identify target antibody pairs. The company operates with a relatively small to mid-sized team.

Its asset pipeline includes KBA1412 in Phase I and additional programs in preclinical development. A recent development is a collaboration and license option with Sanofi announced in July 2025 to use the B cell platform for antibody and epitope discovery.

Get verified Kling Biotherapeutics emails free

Company overview Employee directory